|LETTER TO THE EDITOR
|Year : 2020 | Volume
| Issue : 1 | Page : 33-34
Anticalcitonin gene-related peptide monoclonal antibodies: An overview
Jamir Pitton Rissardo, Ana Letícia Fornari Caprara
Department of Neurology; Department of Medicine, Federal University of Santa Maria, Santa Maria, Rio Grande do Sul, Brazil
|Date of Submission||19-Oct-2019|
|Date of Decision||16-Nov-2019|
|Date of Acceptance||24-Nov-2019|
|Date of Web Publication||14-Jan-2020|
Jamir Pitton Rissardo
Rua Roraima 1000, Santa Maria, Rio Grande do Sul
Source of Support: None, Conflict of Interest: None
|How to cite this article:|
Rissardo JP, Fornari Caprara AL. Anticalcitonin gene-related peptide monoclonal antibodies: An overview. APIK J Int Med 2020;8:33-4
|How to cite this URL:|
Rissardo JP, Fornari Caprara AL. Anticalcitonin gene-related peptide monoclonal antibodies: An overview. APIK J Int Med [serial online] 2020 [cited 2020 Jan 23];8:33-4. Available from: http://www.ajim.in/text.asp?2020/8/1/33/275984
We read the article “Chronic Migraine: Erenumab, New Kid on the Block” on the esteemed “APIK Journal of Internal Medicine” with great interest. In the article, Goel reviewed the new drug erenumab that has been approved by the Food and Drug Administration (FDA) in the last year.
Headaches substantially affect the quality of life, causing disability in patients. In this context, migraine is a primary headache disorder that can occur episodic or chronic. The development of new therapies to this disease was limited throughout the years; first, the oral medication; after that occurred the approval of botulinum toxin. In 2018, the anticalcitonin gene-related peptide (anti-CGRP) monoclonal antibodies were available.
Here, we would like to do a table with the other anti-CGRP antibodies already approved by the FDA that together with the study of Goel could lead to a better comprehension of the management of this group of medications [Table 1].,,,, It is worthy of mentioning that due to the price, the majority of the insurance companies in the United States will request a previous trial of 2–4 drugs before releasing the anti-CGRP. In addition, most of the studies only started these medications after the failure of at least four drugs, so these molecules are not still the first drug of choice, and they are indicated only in refractory cases.,
Financial support and sponsorship
Conflicts of interest
There are no conflicts of interest.
| References|| |
Go Goel D. Chronic migraine: Erenumab, new kid on the block. APIK J Int Med 2019;7:142-4. [Full text]
Yuan H, Lauritsen CG, Kaiser EA, Silberstein SD. CGRP monoclonal antibodies for migraine: Rationale and progress. BioDrugs 2017;31:487-501.
Scuteri D, Adornetto A, Rombolà L, Naturale MD, Morrone LA, Bagetta G, et al
. New trends in migraine pharmacology: Targeting calcitonin gene-related peptide (CGRP) with monoclonal antibodies. Front Pharmacol 2019;10:363.
Saper J, Lipton R, Kudrow D, Hirman J, Dodick D, Silberstein S, et al
. Primary Results of PROMISE-1 (Prevention of Migraine Via Intravenous Eptinezumab Safety and Efficacy–1) Trial: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Eptinezumab for Prevention of Frequent Episodic Migraines (S20. 001). AAN Enterprises; 2018.
Goadsby PJ, Reuter U, Hallström Y, Broessner G, Bonner JH, Zhang F, et al
. A controlled trial of erenumab for episodic migraine. N Engl J Med 2017;377:2123-32.
Deen M, Correnti E, Kamm K, Kelderman T, Papetti L, Rubio-Beltrán E, et al
. Blocking CGRP in migraine patients – A review of pros and cons. J Headache Pain 2017;18:96.